Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alexa B. Schrock, PhD"'
Autor:
Shannon S. Zhang, MD, Alexa B. Schrock, PhD, Misako Nagasaka, MD PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100453- (2023)
Externí odkaz:
https://doaj.org/article/42bf59772e3b4a79b0a1df9d44054573
Autor:
Shannon S. Zhang, MD, Jessica K. Lee, MSc, Hanna Tukachinsky, PhD, Alexa B. Schrock, PhD, Misako Nagasaka, MD, PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100387- (2022)
Introduction: Germline CHEK2 mutations are rare and have not been associated with increased risk of NSCLC. Methods: We identified two sequential primary NSCLCs harboring distinct actionable driver alterations (EGFR E746 _S752 delinsV and CD74-ROS1) i
Externí odkaz:
https://doaj.org/article/e5774861fb6d4b509b5508a9a6e29a18
Autor:
Barbara J. Gitlitz, MD, Silvia Novello, MD, PhD, Tiziana Vavalà, MD, Marisa Bittoni, PhD, Alicia Sable-Hunt, RN, MBA, Dean Pavlick, BS, Robert Hsu, MD, S. Lani Park, PhD, MPH, Ruthia Chen, BA, Matthew Cooke, BA, Amy Moore, PhD, Alexa B. Schrock, PhD, Joan H. Schiller, MD, Bonnie J. Addario, Geoffrey R. Oxnard, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100194- (2021)
Introduction: Lung adenocarcinomas in young patients (
Externí odkaz:
https://doaj.org/article/01195660439e4b838be16ffce4fceb8b
Autor:
Viola W. Zhu, MD, PhD, Misako Nagasaka, MD, Russell Madison, BA, Alexa B. Schrock, PhD, Jean Cui, PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100116- (2021)
Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired ALK resistance mutations, including the solvent-front mutation G1202R. Here, we report, for the first time, a novel, sequentially-evolved EML4-ALK variant
Externí odkaz:
https://doaj.org/article/0f88699f4ca44685b12f532982b48a21